Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ER positive
i
Other names:
ESR1, Era, ESR, NR3A1, ER, ER beta
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2099
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(198)
News
Trials
Search handles
@BijoyTelivala
@CarmenCriscit
@DrGattiMays
@DrHBurstein
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@EMittendorfMD
@FilippoMontemu1
@FuenteApolo
@GlopesMd
@KefahMokbel
@KrishanJethwa
@MCristofanill
@Maherjane
@Monthy_A
@NagiSaghir
@RCaponero
@Rndubois
@SirohiBhawna
@SuyogCancer
@UmutDisel
@VivekSubbiah
@antgiorda
@cancermedic
@doctorC369
@dr_yakupergun
@elmayermd
@jamecancerdoc
@jhaveri_komal
@mabelonc
@maryam_lustberg
@mtmdphd
@naborala
@nlinmd
@oreganruth
@prat_aleix
@protoninfo
@radioncoluis
@tmprowell
@weldeiry
Search handles
@BijoyTelivala
@CarmenCriscit
@DrGattiMays
@DrHBurstein
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@EMittendorfMD
@FilippoMontemu1
@FuenteApolo
@GlopesMd
@KefahMokbel
@KrishanJethwa
@MCristofanill
@Maherjane
@Monthy_A
@NagiSaghir
@RCaponero
@Rndubois
@SirohiBhawna
@SuyogCancer
@UmutDisel
@VivekSubbiah
@antgiorda
@cancermedic
@doctorC369
@dr_yakupergun
@elmayermd
@jamecancerdoc
@jhaveri_komal
@mabelonc
@maryam_lustberg
@mtmdphd
@naborala
@nlinmd
@oreganruth
@prat_aleix
@protoninfo
@radioncoluis
@tmprowell
@weldeiry
Filter by
Latest
8ms
For me, I have restrained giving adjuvant chemotherapy to women over 60 with resected zero or few positive node breast cancer that was heavily ER positive. I thought Tamoxifen or AI was sufficient. Pretty much every other oncologist in town gave chemotherapy. Seemed excessive. (@davideyoungmd)
8 months ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
|
tamoxifen
8ms
🎥@MichaelGnant of @MedUni_Wien discusses late recurrences in ER-positive breast cancer at #ASCO23. Optimal treatment duration is 7-8 years, with 10 years for high-risk cases. The carryover effect brings long-lasting benefits: ➡️https://t.co/OG8RHYWG95⬅️ #BreastCancer #BCSM (@VJOncology)
8 months ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
8ms
Excellent panel discussion for Session IV on ER Positive Breast Cancer in the #HarvardBreastCancerCourse. #PabloLeone @PTarantinoMD @elmayermd @alex_toker @christinaminami @RMJesel @BeverlyMoy @drsarahsam (@DFCI_BreastOnc)
8 months ago
ER (Estrogen receptor)
|
ER positive
9ms
If you're looking for a quick overview of the latest advances in ER+ breast cancer treatment options, check out this money slide! It captures all the recent updates in one glance @AkshjotP @bmtdoc63 @binayshah @OncoAlert @btfoundation #breastcancer #ERpositive #cancerresearch https://t.co/el9xNm5Bng (@VivekSubbiah)
9 months ago
ER (Estrogen receptor)
|
ER positive
9ms
@ASCO Educational Book provides insightful summaries with great impact on clinical practice! @ABCSGVienna President @MichaelGnant contributes with an overview – based on his ASCO talk – on managing ER-positive breast cancer and challenges of late relapse. https://t.co/mwD3euw9w2 (@ABCSGVienna)
9 months ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
9ms
New📰published: AMEERA-3: Randomized Phase II Study of Amcenestrant Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. @stolaney1 and colleagues. https://t.co/QqL6DtT4C7 (@DFCI_BreastOnc)
9 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR positive
|
amcenestrant (SAR439859)
10ms
Check out Dr. Michail Ignatiadis @MIgnatiadis @JulesBordet discussing #ASCO23 Primary Efficacy Analyses of NeoRHEA, #Neoadjuvant #Biomarker Research Study of Palbociclib w/Endocrine Therapy in Estrogen Receptor Positive/HER2- BC #bcsm #breastcancer @EORTC https://t.co/iwysbmWmEj (@Sameh_VuMedi)
10 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative
|
Ibrance (palbociclib)
10ms
In this video, Adam Brufsky, MD, PhD, FACP, discusses palbociclib as a treatment option for patients with ER-positive, HER2-negative, advanced breast cancer. #bcsm | @UPMCHillmanCC @breastoncdoc @UPMCnews https://t.co/hl2rtyvCfz (@TargetedOnc)
10 months ago
Clinical • Video • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
Ibrance (palbociclib)
10ms
Not to miss at #ASCO23: Today: Education Session Hall D1: Managing a Long and Winding Road: ER-Positive Breast Cancer Hear @MichaelGnant Editor-in-Chief of Breast Care, speak on Late Recurrences in ER-Positive Breast Cancer: What Else Can We Do? #BreastCancer @KargerPublisher (@OncoKarger)
10 months ago
ER (Estrogen receptor)
|
ER positive
10ms
SCI member Allison Kurian & others found screening for risk-reducing medication could decrease the risk of #BreastCancer death. https://t.co/LSP2ypKHDu @AllisonKurian #ERpositive (@SCIDirector)
10 months ago
ER (Estrogen receptor)
|
ER positive
10ms
Guideline Update Provides New Testing & Tx Recx for Pts w/ ER-Positive, HER2-Negative Met Breast Cancer w/ ESR1 Mutations [May 17-18, 2023] @ASCO Daily News - https://t.co/3ZVrEkQEN5 @DrHBurstein et al. @JCO_ASCO https://t.co/68e7D0CSgU #bcsm #PrecisionMedicine #LiquidBiopsy (@mtmdphd)
10 months ago
Clinical • Liquid biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER mutation • ESR1 mutation
11ms
Is this for ER positive disease, what about TNBC? Is it the same across the board...I have a suspicion it is not. #TumorBoardTuesday (@HannahAlison20)
11 months ago
ER (Estrogen receptor)
|
ER positive
11ms
Adjuvant abemaciclib should not be prescribed to women with high-risk, oestrogen-receptor positive breast cancer. Lancet Oncol 2023 - Published Online, May 2, 2023 https://t.co/tlMyjFON4t (@RCaponero)
11 months ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
|
Verzenio (abemaciclib)
11ms
@ASCO #ASCO23 #ASCODailyNews ER-Positive Breast Cancer: Assessing Late Relapse and Moving Treatment Forward https://t.co/0vIqH2EzGs (@GlopesMd)
11 months ago
ER (Estrogen receptor)
|
ER positive
11ms
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? An excellent review👇 https://t.co/WEdbZlHexv (@dr_yakupergun)
11 months ago
Review
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER positive + HER-2 negative
11ms
This is the updated #algorithm we used during our discussion w/ @DrGattiMays for HR+ #BreastCancer #sacituzumab (or is it “sassy toucan”) #elacestrant #TDxD #ERPositive #bcsm #OncTwitter #OncEd #MedTwitter @OncoAlert https://t.co/fslueYjU6H (@OncBrothers)
11 months ago
ER (Estrogen receptor)
|
ER positive
|
Orserdu (elacestrant)
11ms
Thank you @OncBrothers for having me on the podcast to discuss #ERpositive #mBC #bcsm @OhioStateMedOnc @OSUCCC_James (@DrGattiMays)
11 months ago
ER (Estrogen receptor)
|
ER positive
12ms
The proceedings from Dr. Tolaney's (@stolaney1) recent Meet The Professor webinar series, focusing on the management of ER-positive and triple-negative #breastcancer, is now available online⬇️ https://t.co/RJruNurQMk (@DFCI_BreastOnc)
12 months ago
ER (Estrogen receptor)
|
ER positive
1year
Household income linked to recurrence score, mortality in #ERPositiveBreastCancer Anurag K. Singh MD, @Single_Fx_Singh et al. @RoswellPark https://t.co/dEPn29yXDS @GoHealio (@RMilesMD)
1 year ago
ER (Estrogen receptor)
|
ER positive
1year
#Household #income linked to #recurrence score, mortality in ER-positive #breastcancer: https://t.co/FH5eyQ41fR (@Rndubois)
1 year ago
ER (Estrogen receptor)
|
ER positive
1year
“Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer” with Erika P. Hamilton, MD https://t.co/uHJqoFA5bB @ErikaHamilton9 @SarahCannonDocs #breastcancer (@clinadvances)
1 year ago
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
1year
Does the “1 breast cancer death avoided by year 15 for every 4 recurrences avoided by year 10” apply for a more favorable cohort of elderly patients with ER positive disease? Wondering if the more “refined” cohort in the current era of systemic tx would differ? Possibly??? (@KrishanJethwa)
1 year ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
1year
Don't miss this Research to Practice Meet the Professor talk with Dr. Sara Tolaney (@stolaney1) on Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer on Tuesday, March 7, 2023, 5:00 PM- 6:00 PM ET https://t.co/rSUyIJZG3K @DrNeilLove (@DFCI_BreastOnc)
1 year ago
ER (Estrogen receptor)
|
ER positive
1year
Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older. https://t.co/Pt3sX51do2 (@radioncoluis)
1 year ago
Clinical • HEOR • Cost effectiveness
|
ER (Estrogen receptor)
|
ER positive
1year
Women with ER-negative primary breast cancers are at higher risk of second breast cancers than women with ER-positive cancers during the first 5 years after diagnosis. Read more: https://t.co/Ppp5HmrLrd @oncoalert @oreganruth #BCSM (@JournalCancer)
1 year ago
ER (Estrogen receptor)
|
ER positive • ER negative
1year
WATCH: @VKaklamani, of @UTHealthSA, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer. #bcsm #oncology https://t.co/LZEgCdDY5I (@OncLive)
1 year ago
ER (Estrogen receptor)
|
ER positive
1year
Goodness - if chemo benefit due to hormone effects , does this mean we could go back to ovarian ablation without chemotherapy for ER positive breast cancer ? #stgalen (@Maherjane)
1 year ago
ER (Estrogen receptor)
|
ER positive
1year
Hear ye, hear ye! Important Estrogen receptor degraded approved for ESR1 mutated breast cancers. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer | FDA https://t.co/LYNgE4gNJT (@Dr_R_Kurzrock)
1 year ago
FDA event • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER mutation • ESR1 mutation
|
Orserdu (elacestrant)
1year
For pts getting solid tumor NGS for other reasons, would you trust the NGS if ESR1 positive, or would you still get the Guardant360? ()
1 year ago
Clinical • Next-generation sequencing
|
ER (Estrogen receptor)
|
ER positive
|
Guardant360® CDx
1year
.@cwspeers et al find sensitivity-to-endocrine-therapy (SET2,3) index prognostic w @SWOG S8814 data, independent of 21-gene RS. Two Methods Studied in Defining Prognosis for Patients With ER-Positive, Node-Positive #BreastCancer - The ASCO Post https://t.co/J8MIqEbAQ4 (@SWOG)
1 year ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
1year
First oral SERD elacestrant (Orserdu) approved by @FDAOncology for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer https://t.co/ZzTSAkpyPd (@cancermedic)
1 year ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER mutation • ESR1 mutation
|
Orserdu (elacestrant)
1year
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer https://t.co/edGR6cR3Sk (@MCristofanill)
1 year ago
FDA event • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER mutation • ESR1 mutation
|
Orserdu (elacestrant)
1year
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer | Journal of Clinical Oncology @dradityabardia ! Now FDA approved 👏🏼 https://t.co/ire7VZ8L53 (@VivekSubbiah)
1 year ago
Clinical • FDA event • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
Orserdu (elacestrant)
1year
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer @OncoAlert @FDAOncology @ASCO (@jamecancerdoc)
1 year ago
FDA event • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER mutation • ESR1 mutation
|
Orserdu (elacestrant)
1year
High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer https://t.co/V9r165wktg (@weldeiry)
1 year ago
ER (Estrogen receptor) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
ER positive
1year
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer https://t.co/PV5cbg6DdM This sounds really promising! (@FilippoMontemu1)
1 year ago
ER (Estrogen receptor)
|
ER positive
|
Verzenio (abemaciclib) • letrozole
1year
Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy. #bcsm #SABCS22 | @UTHealthSAMDA @VKaklamani https://t.co/Y6ujtNYpQx (@TargetedOnc)
1 year ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
|
Orserdu (elacestrant)
1year
De-escalation for Low-Risk ER-positive Early-Stage Breast Cancer in Women Age 65 and Older: Ultra-Hypofractionated Whole Breast Radiation Therapy Alone is more cost-effective than Endocrine Therapy Alone or Combined Treatment #radonc #bcsm https://t.co/kU6M86MmiS (@Monthy_A)
1 year ago
Clinical • HEOR • Cost effectiveness
|
ER (Estrogen receptor)
|
ER positive
1year
Now available! Video Recording and Slides from a Research to Practice #SABCS22 event on Optimizing the Management of ER-Positive and Triple Negative Breast Cancer. #TNBC #BreastCancer #bcsm @stolaney1 @ErikaHamilton9 https://t.co/reIsd8YBiC (@DFCI_BreastOnc)
1 year ago
Video
|
ER (Estrogen receptor)
|
ER positive
over1year
Er positive pts . How can we do better ? Can we avoid chemo for elderly? Whom to give extended endocrine therapy ? @SABCSSanAntonio #SABCS22 @OncoAlert (@SuyogCancer)
over 1 year ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
over1year
Take homes are 1) BCI (MGI + H/I) prognostic for distant recurrence in premenopausal patients with ER-positive early stage breast cancer and 2) BCI (h/I) low predictive of OFS benefit. Further validation planned. (@oreganruth)
over 1 year ago
Clinical
|
ER (Estrogen receptor)
|
ER positive
over1year
Earlier this week, @VKaklamani, MD, leader of the @UTHealthSAMDA breast cancer program & co-director of the @SABCSSanAntonio, presented the Phase III results of the EMERALD trial evaluating a novel oral drug therapy for metastatic ER-positive/HER2-negative breast cancer. #SABCS22 (@UTHealthSAMDA)
over 1 year ago
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login